NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee C meeting minutes

**Minutes:** Confirmed

**Date:** Tuesday 14 February 2023

**Location:** Via Zoom

## Attendees

Committee members present

1. Professor Stephen O’Brien (Chair) Present for all items
2. Dr Richard Nicholas (Vice Chair) Present for all items
3. Dr Britta Stordal Present for all items
4. Dr Alex Cale Present for all items
5. Michael Chambers Present for all items
6. Dr Mark Corbett Present for all items
7. Dr Prithwiraj Das Present for all items
8. Chamkhor Dhillon Present for all items
9. Dr Pedro Saramago Goncalves Present for all items
10. John Hampson Present for all items
11. Dr Nigel Langford Present for all items
12. Dr Steven Lloyd Present for all items
13. Iain McGowan Present for all items
14. Ugochi Nwulu Present for all items
15. Stella O’Brien Present for all items
16. Professor Andrew Renehan Items 1 to 5.2.2
17. Dr Arpit Srivastava Present for all items
18. Professor Matthew Stevenson Items 5 to 6.2.2
19. Professor Paul Tappenden Present for all items

NICE staff (key players) present

Ross Dent, Associate Director Present for all items

Jasdeep Hayre, Associate Director Items 1 to 4.2.2

Louise Jafferally, Project Manager Items 5 to 6.2.2

Celia Mayers, Project Manager Items 1 to 4.2.2

Sally Doss, Heath Technology Assessment Adviser Items 1 to 4.2.2

Owen Swales, Heath Technology Assessment Adviser Items 5 to 5.2.2

Albany Chandler, Heath Technology Assessment Analyst Items 1 to 4.2.2

Alex Filby, Heath Technology Assessment Analyst Items 6 to 6.2.2

George Millington, Heath Technology Assessment Analyst Items 6 to 6.2.2

Benjamin Gregory, Business Analyst, Resource Impact Present for all items

Korin Knight, Senior Medical Editor Items 1 to 4.2.2

Anna Sparshatt, Senior Medical Editor Items 6 to 6.2.2

Ella Fitzpatrick, Public Involvement Adviser Items 1 to 4.1.3

Emma Gordon, Coordinator, Corporate Office Items 1 to 4.1.3 & 6 to 6.1.3

Rosalee Mason, Coordinator, Corporate Office Items 5 to 5.1.3

Gemma Smith, Coordinator, Committee Operations Present for all items

Iain Cannell, Administrator, Technology Appraisals Items 5 to 6.2.2

Leah Kelly, Administrator, Technology Appraisals Items 1 to 4.2.2

NICE staff (observers) present

Milena Wobbe, Technical Analyst, Managed Access Present for all items

Catrin Austin, Technical Analyst, Methods, & Economics Items 1 to 4.2.2 & 6 to 6.2.2

Thomas Palmer, Technical Analyst, Interventional Procedures Items 5 to 5.2.2

Emily Eaton-Turner, Technical Adviser, Commercial Liaison Items 6.1.3 to 6.2.2

External assessment group representatives present

Matt Stevenson, School of Health and Related Research (ScHARR) Items 1 to 4.1.3

Robert Wolff, Kleijnen Systematic Reviews Ltd (KSR) Items 5 to 5.1.3

Isaac Corro Ramos, Kleijnen Systematic Reviews Ltd (KSR) Items 5 to 5.1.3

Dwayne Boyers, Aberdeen HTA Group Items 6 to 6.1.3

Neil Scott, Aberdeen HTA Group Items 6 to 6.1.3

Clinical, Patient & NHS England experts present

Professor Peter Clark, Cancer Drug Fund Clinical Lead, NHS England, Present for all items

Professor David Marks, Director Bristol BMT Unit/Head ALL program, Clinical expert, nominated by Kite, Items 1 to 4.1.3

Sophie Wheldon, Patient expert, nominated by Leukaemia Care, Items 1 to 4.1.3

Dr Deborah Yallop, Consultant Haematologist, clinical expert, nominated by NCRI-ACP-RCP-RCR, Items 1 to 4.1.3

## Minutes

### Introduction to the meeting

* 1. The chair Professor Stephen O’Brien welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted apologies from Dr David Foreman, Iftab Akram and Dr Rob Forsyth.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meetings held on Tuesday 17 January and Tuesday 24 January 2023.

### Appraisal of autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over [ID1494]

* 1. Part 1 – Open session
		1. The chair welcomed the invited experts, external assessment group representative, members of the public and company representatives from Kite, a Gilead company
		2. The chair asked all committee members and experts, external assessment group representative and NICE staff present to declare any relevant interests in relation to the item being considered.
		+ Committee member Michael Chambers declared financial interests as he has participated in an advisory panel for Pfizer (possible comparator), in an unrelated disease area (prostate cancer). It was agreed his declaration would not prevent Michael from participating in discussions on this appraisal.
		+ Committee member Dr Richard Nicholas declared financial interests as he has carried out paid advisory boards with Novartis in an unrelated area - multiple sclerosis. It was agreed his declaration would not prevent Dr Nicholas from participating in discussions on this appraisal.
		+ Committee member Stella O’Brien declared personal interests as she is a member of the Genetics Alliance UK PPIE Working Group on ATMPs affiliated with CATAPULT cell and gene therapy to encourage the integration of PPIE throughout the research cycle from the earliest stages and onwards. CATAPULT is a network of not-for profit, independent centres which connect businesses with the UK’s research and academic communities. Although CAR-T therapies are an example of ATMPs, I have not contributed to work on CAR-T therapies with this group. It was agreed her declaration would not prevent Stella from participating in discussions on this appraisal.
		+ Committee member Professor Paul Tappenden declared non-financial professional interests as he works for ScHARR (EAG for this topic), and he provided a peer review of the draft ERG report. It was agreed that his declaration means he could contribute to the discussion but not take part in any vote.
		+ Nominated clinical expert Dr Deborah Yallop declared the following interests:
* She has received honoraria for advisory board for Kite Gilead and Pfizer
* She has received financial support to attend meetings from Amgen, Servier, Jazz
* She provides Project support to Servier
* She is a principal investigator KCH AUTO-1 trial (Autolus)
* She has been co-investigator on the CALM trial (Servier)).

It was agreed her declarations would not prevent Dr Yallop from providing expert advice to the committee.

* + - Nominated clinical expert Professor David Marks declared financial interests as he has been remunerated for work for Pfizer, Amgen, Novartis, and Kite in the area of ALL It was agreed his declarations would not prevent Professor Marks from providing expert advice to the committee
		- Nominated patient expert Sophie Wheldon declared the following interests:
* She took part in a patient and carer insights workshop on CAR T with Janssen in mid-2021 and received £240
* She has been diagnosed with ALL and received CAR-T therapy.
* She is employed by the nominating organisation Leukaemia Care who in the last 12 months received funding from Amgen, Incyte, Novartis, and Pfizer.

It was agreed her declarations would not prevent Sophie from providing expert advice to the committee

* + - No further interests were declared for this appraisal.
		1. The Chair led a discussion of the consultation comments presented to the committee.
	1. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representative and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Document (FAD). The committee decision was reached through a vote by members.
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Document (FAD in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10424>

### Appraisal of tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma [ID3795]

* 1. Part 1 – Open session
		1. The chair Professor Stephen O’Brien welcomed the invited the NHS England expert, external assessment group representatives, members of the public and company representatives from Incyte.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
		+ Committee Michael Chambers declared financial interests as in collaboration with Univ. Utrecht has co-ordinated a training programme for Roche in Real World Evidence, which did not consider any Roche products, he also participated in an advisory panel for Pfizer in an unrelated disease area (prostate cancer) and provided consulting advice to Sanofi, again in an unrelated disease area. It was agreed that his declaration would not prevent Michael from participating in discussions on this appraisal
		+ Committee member Dr Richard Nicholas declared financial interests as he has attended paid advisory boards with Novartis and Roche (named comparator companies) in an unrelated disease area. It was agreed that his declaration would not prevent Dr Nicholas from participating in discussions on this appraisal
		+ No further interests were declared for this appraisal.
		1. The Chair led a discussion of the consultation comments presented to the committee.
	2. Part 2– Closed session (company representatives, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10645>

### Appraisal of axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 1 systemic therapy [ID1684]

* 1. Part 1 – Open session
		1. The chair Professor Stephen O’Brien welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Kite, a Gilead company
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
		+ Committee member Stella O’Brien declared personal interests as she is a is a member of the Genetics Alliance UK PPIE Working Group on ATMPs affiliated with CATAPULT cell and gene therapy to encourage the integration of PPIE throughout the research cycle from the earliest stages and onwards. CATAPULT is a network of not-for profit, independent centres which connect businesses with the UK’s research and academic communities. Although CAR-T therapies are an example of ATMPs, she has not contributed to work on CAR-T therapies with this group. It was agreed that her declaration would not prevent Stella from participating in discussions on this appraisal.
		+ Committee member Dr Richard Nicholas declared financial interests as he has attended paid advisory boards with Novartis and Roche (named comparator companies) in an unrelated disease area. It was agreed that his declaration would not prevent Dr Nicholas from participating in discussions on this appraisal
		+ No further interests were declared for this appraisal.
		1. The Chair led a discussion of the consultation comments presented to the committee.
	2. Part 2 Closed session (company representatives, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached through a vote by members.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: https://www.nice.org.uk/guidance/indevelopment/gid-ta10580

### Date of the next meeting

The next meeting of the Technology Appraisal Committee C will be held on Tuesday 14 March 2023 and will start promptly at 09:30.